The Alternative Name for Wegovy — and Why It Matters

The misconception worth correcting: Wegovy and Ozempic are not interchangeable

A remarkably common belief is that Wegovy and Ozempic are simply different names for the same medicine, and that if one is available, it can stand in for the other. It's an easy assumption to reach. Both contain semaglutide, both come from Novo Nordisk and both circulate in the same conversations online. The truth is more precise, and the difference matters legally as much as clinically.

Ozempic is licensed in the UK for type 2 diabetes. Wegovy is licensed for weight management. The MHRA grants each licence separately, for a specific indication at a specific dose. Prescribing Ozempic for weight loss would be an off-label use and falls outside the scope of the weight-management licence. The NHS semaglutide medicines page sets out this distinction clearly, covering both the weight-loss and diabetes formulations. So when someone asks for the alternative name for Wegovy, the honest answer is semaglutide, not Ozempic, and not Rybelsus (the oral semaglutide tablet licensed for diabetes, discussed separately below).

You can explore how Wegovy compares with Ozempic in more depth if that question is on your mind. The short version: the molecule is the same; the licence, the dose and the legal context are not.

Semaglutide's other brand names, and what each one is actually for

Once you know semaglutide is the generic, the brand landscape becomes easier to map. There are currently three semaglutide brand names active in the UK, each tied to a different indication and dose range.

Wegovy, subcutaneous injection, weight management, titrated from 0.25 mg up to 2.4 mg weekly (or the 7.2 mg pen approved by the MHRA in April 2026 for adults with a BMI of 30 or above). This is the formulation for weight loss, and the one covered across the Wegovy section of our site.

Ozempic, subcutaneous injection, type 2 diabetes. Licensed at doses up to 2 mg weekly. Not a weight-loss medicine in UK law, regardless of how it is sometimes described in the press.

Rybelsus, oral tablet, type 2 diabetes, at 3 mg, 7 mg and 14 mg daily. Completely separate from Wegovy tablets: the newly approved Wegovy tablet (oral semaglutide for weight management, MHRA-licensed June 2026) has a different dosing schedule (1.5 mg up to 25 mg daily) and different strengths. Mixing up Rybelsus and Wegovy tablets is one of the more consequential confusions in this space, so it is worth being precise.

Understanding which brand does what is also relevant when you review the full picture of Wegovy's brand identity, or when a search turns up results about the various names used for semaglutide weight-loss treatment.

Why clinical papers and prescriptions use 'semaglutide', not 'Wegovy'

If you have read any of the trial evidence for this medicine, you will have noticed that researchers write semaglutide throughout. The landmark STEP 1 trial (published in the New England Journal of Medicine and the foundation for NICE's recommendation) refers to semaglutide 2.4 mg as the study drug, reporting roughly 15% average body-weight reduction over 68 weeks. NICE's technology appraisal for the weight-management licence (TA875) does the same. Your prescription, if issued, will name semaglutide as the active substance, with Wegovy as the brand.

This matters practically. If you are comparing treatment options, checking eligibility criteria or reading a safety communication from the MHRA, you need to know that semaglutide is the search term that will return the most complete picture. A search for Wegovy alone may miss broader guidance written under the generic name. The relationship between Wegovy's names is worth understanding before starting any conversation with a prescriber.

On the cost side, Wegovy pricing in the UK private market is set by providers and varies by dose, which is another context where seeing the generic name on a quote can cause confusion, it is the same medicine.

One practical note for day-to-day use: if constipation becomes an issue during treatment, our page on managing constipation alongside Wegovy covers what the evidence supports. And if you have questions about technique, such as whether to pinch the skin when injecting, those answers are also available separately.

Starting treatment: what the generic name means for your consultation

When you speak to a prescriber about semaglutide for weight management, they are assessing you for Wegovy, the licensed brand. A GPhC-registered Independent Prescriber reviews your full health picture: BMI, weight-related conditions, current medicines and relevant history. The NICE-recommended thresholds for NHS access require a BMI of 35 or above with at least one weight-related comorbidity, within a specialist service, for a maximum of two years. Private prescribing follows the licensed criteria from the SmPC, broadly BMI of 30 or above, or 27 to 29.9 with a qualifying condition. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance.

A private route through a regulated online pharmacy means no referral and no waiting list, subject to clinical suitability. Knowing the alternative name for Wegovy is semaglutide puts you in a stronger position going into that conversation: you can read the trial evidence clearly, understand your prescription and ask the right questions. If you are ready to take that step, you can speak to our prescribers through a free consultation, reviewed the same day by a real clinician. Our overview of weight-loss treatments sets out the full landscape if you want to compare options first.